A phase I dose-escalation, pharmacokinetic (PK), and pharmacodynamic (PD) evaluation of intravenous LY2090314 a GSK3 inhibitor administered in combination with pemetrexed and carboplatin.
L. H. Brail
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
J. E. Gray
Consultant or Advisory Role - Lilly
Honoraria - Lilly
H. Burris
No relevant relationships to disclose
G. R. Simon
Consultant or Advisory Role - Lilly
Honoraria - Lilly
J. Cooksey
No relevant relationships to disclose
S. F. Jones
No relevant relationships to disclose
D. Farrington
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
T. Lam
Consultant or Advisory Role - Lilly
K. Jackson
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
K. Chow
Employment or Leadership Position - Lilly
J. T. Brandt
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
J. R. Infante
No relevant relationships to disclose